WASHINGTON Novavax of Maryland, which won a federal contract worth $1.75 billion to develop and manufacture a coronavirus vaccination, announced on Thursday that it would no longer be funded by the federal government until Novavax resolves any concerns raised by federal regulators.In a quarterly filing to the Securities and Exchange Commission, the firms disclosed their financial information. As part of its crash vaccine program, the Trump administration purchased 110 million doses from Novavax.Novavax reported that its vaccine was effective against Covid-19 symptoms in June, but it has been struggling for months to mass-produce its product. The vaccine is not yet authorized for distribution in the United States. Federal officials stated that it is uncertain when or if it will.Four Novavaxs employees said that the company has so far been unable to prove its production process meets Food and Drug Administration standards. The two spoke under anonymity to discuss sensitive contracting issues.
